Prognostic significance of cellular and molecular genetic abnormalities in pediatric core binding factor-acute myeloid leukemia

Core binding factor-acute myeloid leukemia (CBF-AML) is a common cellular genetic subtype in children with acute myeloid leukemia (AML), accounting for 25%-30% of AML, and it has a good clinical prognosis. However, there are still 30%-40% of CBF-AML patients with recurrence, and the cellular molecular genetic abnormal events accompanying such patients may be related to their clinical prognosis. At present, dasatinib has been reported in the therapy of adult CBF-AML. Different molecular genetic backgrounds have become a new idea for precise targeted therapy, but there are still few related studies on pediatric CBF-AML. The author summarizes clinical prognostic impacts of cellular and molecular genetic abnormalities which are commonly seen in pediatric CBF-AML, aiming to provide new ideas for individualized treatment of pediatric CBF-AML. Key words: Core binding factors; Leukemia, myeloid, acute; Chromosome aberrations; Prognosis; Child